The Food and Drug Administration recently approved a new vaccine from Moderna, but the stock dipped in response. The shortened trading week that ended on May 31 was a strange one for the vaccine developer Moderna (MRNA -5.90%). Biotech stocks generally rise after a product they spent years developing earns marketing approval, but this isn't what happened. Why Moderna stock fell Moderna's bizarre stock price performance during the week ending May 31 had two main factors. First, enthusiasm for the vaccine dev ...

This news could be worth billions... Moderna (MRNA -5.90%) jumped into the limelight when it started developing a coronavirus vaccine candidate. And the stock soared as the vaccine raced across the finish line and went on to bring in billions of dollars in earnings. But in later pandemic days, investors started worrying about Moderna's dependence on its only commercialized product, and that has weighed on the stock price. Shares of the biotech company have dropped 70% from their high back in 2021. Moderna m ...

Moderna, Inc. (NASDAQ:MRNA) Bernstein's 40th Annual Strategic Decisions Conference May 31, 2024 10:00 PM ET Company Participants Stephane Bancel - CEO Conference Call Participants Courtney Breen - Bernstein Courtney Breen Hi, there, everyone. It's great to see you all on Friday of the conference. I'm Courtney Breen, I'm the U.S. biopharma analyst here at Bernstein. I am privileged today to be sharing the stage with Stephane Bancel, the CEO of Moderna. Stephane has been at the helm of Moderna for the last 13 ...

Moderna's sell-off this week is for the birds. Shares of Moderna (MRNA 2.41%) were sinking 9% lower this week as of Thursday's market close, according to data provided by S&P Global Market Intelligence. The decline appears to be the result of investors taking profits after Moderna stock soared 25% last week. What's behind the big moves for Moderna? Avian flu. Reports of human cases of H5N1 avian flu (also known as bird flu) in Australia and the U.S. caused several vaccine stocks to jump last week. The sell- ...

Forbes Community Guidelines Our community is about connecting people through open and thoughtful conversations. We want our readers to share their views and exchange ideas and facts in a safe space. In order to do so, please follow the posting rules in our site's Terms of Service. We've summarized some of those key rules below. Simply put, keep it civil. Your post will be rejected if we notice that it seems to contain: User accounts will be blocked if we notice or believe that users are engaged in: So, how ...

Biotech stocks are not for the faint of heart. It is a sector that can provide life-changing gains or cause an investment to head towards zero. Between juggling FDA approvals, new product pipelines and regulatory changes, it takes a lot of due diligence to stay on top of which biotech stocks to buy. Some investors even go so far as to look into the more specific clinical phase trials and even learn about the specific medical technology behind each treatment. Over the past few months, biotech stocks have bee ...

Despite the declining top line, shares of Moderna (MRNA) continue to soar thanks to its encouraging pipeline updates and potential product launches over the next few years. The company boasts of a pipeline of more than 40 mRNA-based investigational candidates across different stages of development, targeting multiple indications, including cancer and cardiovascular. Being one of the handful of makers of a COVID-19 vaccine, Moderna reaped the benefits of the COVID-19 pandemic, allowing it to strengthen its c ...

It's not uncommon for companies to face regulatory setbacks -- and It's not the end of the world. Biotech investors aren't fond of regulatory delays. Brand-new products have a limited shelf life before they run out of patent protection. The less time they spend on the market, the less they will generate in sales. But in this The past two-and-a-half years have been rough for Moderna (MRNA 1.58%). Though the biotech was highly successful in the COVID-19 vaccine market, investors rightly expecting this niche t ...

Shares of several vaccine makers soared after reports suggest that the Biden administration is in discussions with Moderna (MRNA) and Pfizer (PFE) to set up a possible vaccine program aimed at preventing the spread of the H5N1 virus, also known as bird flu, in humans. These reports came to light after the discovery of two cases of H5N1 virus in dairy farm workers in Texas and Michigan this year. Both these workers experienced symptoms in the eye after coming into contact with dairy cows infected with the H5 ...

Moderna (NASDAQ:MRNA) stock is up more than 20% in just the past five trading sessions as investors foresee strong growth opportunities for the biotechnology firm. Indeed, the company has climbed 44% so far this year as one of the big winners of 2024's bull market. What's pushing MRNA stock up lately? Well, it appears the company is benefitting primarily from three main drivers: MRNA Stock Climbs Despite Mixed Analyst Ratings While Moderna has plenty of potential growth avenues, some believe MRNA stock may ...